Know Cancer

forgot password

A Prospective Observational Study of Patients With Solitary Plasmacytoma Using a Modified Staging System Supplemented by an MRI and Whole Body FDG-PET Scan

Phase 2
18 Years
Not Enrolling
Multiple Myeloma, Plasmacytoma

Thank you

Trial Information

A Prospective Observational Study of Patients With Solitary Plasmacytoma Using a Modified Staging System Supplemented by an MRI and Whole Body FDG-PET Scan


- Determine the proportion of patients who are misclassified as true solitary
plasmacytoma by MRI and whole-body fludeoxyglucose F 18 positron emission tomography as
a supplement to imaging with skeletal survey.

- Determine the feasibility of accruing patients to this study.

- Determine, preliminarily, biological correlates and prognostic groups that may relate
to progression to symptomatic disease in patients undergoing these imaging procedures.

- Correlate germline genetic polymorphisms with overall clinical course in patients
undergoing these imaging procedures.

OUTLINE: This is a multicenter study.

Within 28 days after study entry, patients undergo gadolinium MRI of the head, spine, and
pelvis (and other sites, if indicated). Patients then receive fludeoxyglucose F 18 IV
followed 90 minutes later by whole-body positron emission tomography (^18FDG-PET) OR
whole-body CT scan/PET. Patients with a confirmed diagnosis of solitary plasmacytoma undergo
MRI and ^18FDG-PET as above at 1 year and then annually for 10 years in the absence of
disease progression (i.e., change of status to solitary plasmacytoma with active myeloma or
biopsy confirmed stage IB or higher multiple myeloma).

After completion of study procedures, patients are followed every 6 months for 10 years.

PROJECTED ACCRUAL: A total of 110 patients will be accrued for this study.

Inclusion Criteria


- Histologically confirmed solitary plasmacytoma of 1 of the following types:

- Solitary bone plasmacytoma

- Extraosseus solitary plasmacytoma

- Bone marrow plasmacytosis < 10% within the past 4 weeks

- Low serum and/or urine M-protein meeting ≥ 1 of the following criteria:

- Serum IgG < 3.5 g/dL

- Serum IgA < 2.0 g/dL

- Urine M-protein (kappa or lambda) < 1.0 g/24 hours

- No lytic lesions on skeletal survey other than a single lesion associated with
solitary plasmacytoma within the past 4 weeks



- 18 and over

Performance status

- Zubrod 0-2

Life expectancy

- Not specified


- Hemoglobin ≥ 10 g/dL* AND/OR

- No hemoglobin 2 g/dL < lower limit of normal* (LLN) NOTE: *Patients with a history of
hemoglobin < 10 g/dL AND/OR < 2 g/dL < LLN that has corrected or improved after
epoetin alfa but requires continued treatment with epoetin alfa are not eligible


- Not specified


- Calcium ≤ 10.5 mg/dL OR

- Calcium normal

- Creatinine ≤ 2 mg/dL


- No other malignancy within the past 5 years except adequately treated basal cell or
squamous cell skin cancer, carcinoma in situ of the cervix or breast, or stage I or
II cancer that is currently in complete remission


Biologic therapy

- Not specified


- Not specified

Endocrine therapy

- No prior high-dose steroids except to relieve neurological compromise


- Prior localized radiotherapy for myeloma allowed

- Concurrent radiotherapy allowed


- Prior surgery for myeloma allowed


- No other prior therapy for myeloma

- Concurrent enrollment in protocol SWOG-S0309 (Myeloma Specimen Repository) allowed

Type of Study:


Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label

Outcome Measure:

proportion of patients misclassified as solitary plasmacytoma

Outcome Time Frame:

2 months

Safety Issue:


Principal Investigator

Andrzej J. Jakubowiak, MD, PhD

Investigator Role:

Study Chair

Investigator Affiliation:

University of Michigan Cancer Center


United States: Federal Government

Study ID:




Start Date:

April 2005

Completion Date:

February 2017

Related Keywords:

  • Multiple Myeloma
  • Plasmacytoma
  • extramedullary plasmacytoma
  • isolated plasmacytoma of bone
  • Multiple Myeloma
  • Neoplasms, Plasma Cell
  • Plasmacytoma



University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan  48109-0752
CCOP - Montana Cancer Consortium Billings, Montana  59101
Mobile Infirmary Medical Center Mobile, Alabama  36640-0460
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences Little Rock, Arkansas  72205
Northern Rockies Radiation Oncology Center Billings, Montana  59101
Hematology-Oncology Centers of the Northern Rockies - Billings Billings, Montana  59101
St. Vincent Healthcare Billings, Montana  59101
Deaconess Billings Clinic - Downtown Billings, Montana  59101
St. James Community Hospital Butte, Montana  59701
Big Sky Oncology Great Falls, Montana  59405
St. Peter's Hospital Helena, Montana  59601
Kalispell Medical Oncology Kalispell, Montana  59901
Kalispell Regional Medical Center Kalispell, Montana  59901
Glacier Oncology, PLLC Kalispell, Montana  59901
Montana Cancer Center at St. Patrick Hospital and Health Sciences Center Missoula, Montana  59802
Montana Cancer Specialists at Montana Cancer Center Missoula, Montana  59802
Community Medical Center Missoula, Montana  59801
Wayne Memorial Hospital, Incorporated Goldsboro, North Carolina  27534
Wayne Radiation Oncology Goldsboro, North Carolina  27534
Wilson Medical Center Wilson, North Carolina  27893-3428
Welch Cancer Center at Sheridan Memorial Hospital Sheridan, Wyoming  82801
Tammy Walker Cancer Center at Salina Regional Health Center Salina, Kansas  67401
Bozeman Deaconess Cancer Center Bozeman, Montana  59715
Billings Clinic Cancer Center Billings, Montana  59107-5100
Sletten Regional Cancer Institute at Benefis Healthcare Great Falls, Montana  59405
Guardian Oncology and Center for Wellness Missoula, Montana  59804